Mati Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $12.1M

Mati Therapeutics General Information

Description

Developer of a novel, non-invasive sustained drug delivery platform designed to deliver medication to the surface of the eye for improved treatment of ocular conditions. The company's platform offers a platform that provides controlled, long-lasting drug release, reducing the need for frequent dosing, enabling patients with glaucoma, dry eye syndrome, ocular allergies, and post-cataract surgery care to experience enhanced treatment adherence and effectiveness.

Contact Information

Formerly Known As
10152012
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 101 Colorado Avenue
  • Suite 2409
  • Austin, TX 78701
  • United States
+1 (512)
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 101 Colorado Avenue
  • Suite 2409
  • Austin, TX 78701
  • United States
+1 (512)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mati Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 08-Oct-2025 $12.1M Completed Clinical Trials - Phase 3
4. Later Stage VC 23-May-2019 Completed Startup
3. Later Stage VC 10-Oct-2018 Completed Startup
2. Early Stage VC 07-Oct-2014 $150K $1.46M Completed Startup
1. Seed Round 12-Apr-2013 $1.31M $1.31M Completed Startup
To view Mati Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Mati Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel, non-invasive sustained drug delivery platform designed to deliver medication to the surface of the
Drug Delivery
Austin, TX
10 As of 2025

Princeton, NJ
 

Vienna, Austria
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mati Therapeutics Competitors (9)

One of Mati Therapeutics’s 9 competitors is TearClear, a Venture Capital-Backed company based in Princeton, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TearClear Venture Capital-Backed Princeton, NJ
Pfizer (Vienna) Corporation Vienna, Austria
EyePoint Corporation Watertown, MA
TearSolutions Venture Capital-Backed Charlottesville, VA
Pfizer Pakistan Corporation Karachi, Pakistan
You’re viewing 5 of 9 competitors. Get the full list »

Mati Therapeutics Patents

Mati Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019245436-A1 Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment Active 29-Mar-2018
AU-2019245436-B2 Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment Active 29-Mar-2018
CA-3095460-A1 Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment Pending 29-Mar-2018
EP-3773330-A1 Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment Active 29-Mar-2018
EP-3773330-A4 Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment Active 29-Mar-2018 A61K9/0051
To view Mati Therapeutics’s complete patent history, request access »

Mati Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mati Therapeutics FAQs

  • When was Mati Therapeutics founded?

    Mati Therapeutics was founded in 2012.

  • Where is Mati Therapeutics headquartered?

    Mati Therapeutics is headquartered in Austin, TX.

  • What is the size of Mati Therapeutics?

    Mati Therapeutics has 10 total employees.

  • What industry is Mati Therapeutics in?

    Mati Therapeutics’s primary industry is Drug Delivery.

  • Is Mati Therapeutics a private or public company?

    Mati Therapeutics is a Private company.

  • What is Mati Therapeutics’s current revenue?

    The current revenue for Mati Therapeutics is .

  • How much funding has Mati Therapeutics raised over time?

    Mati Therapeutics has raised $13.7M.

  • Who are Mati Therapeutics’s competitors?

    TearClear, Pfizer (Vienna), EyePoint, TearSolutions, and Pfizer Pakistan are some of the 9 competitors of Mati Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process